PriceTargets.com logo

Lifecore Biomedical - LFCR Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $9.50
  • Forecasted Upside: 150.66%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$3.79 As of 03/30/2023 01:00 AM ET
▲ +0.42 (12.46%)

This chart shows the closing price for LFCR by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Lifecore Biomedical Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for LFCR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for LFCR

Analyst Price Target is $9.50
▲ +150.66% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Lifecore Biomedical in the last 3 months. The average price target is $9.50, with a high forecast of $11.00 and a low forecast of $8.00. The average price target represents a 150.66% upside from the last price of $3.79.

This chart shows the closing price for LFCR for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 2 polled investment analysts is to buy stock in Lifecore Biomedical.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/6/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/4/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/4/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/3/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/1/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/30/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/28/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/30/2023

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/20/2023Barrington ResearchLower TargetOutperform$10.00 ➝ $8.00Low
3/20/2023StephensDowngradeOverweight ➝ Equal WeightLow
3/17/2023StephensReiterated RatingOverweight$11.00Low
1/11/2023Barrington ResearchLower Target$12.00 ➝ $10.00Low
(Data available from 3/30/2018 forward)

News Sentiment Rating

0.19 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/1/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/1/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/31/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/30/2022
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/30/2022
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
1/29/2023
  • 1 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
2/28/2023
  • 2 very positive mentions
  • 7 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
Mentions as of
3/30/2023

Current Sentiment

  • 2 very positive mentions
  • 7 positive mentions
  • 4 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Lifecore Biomedical logo
Lifecore Biomedical, Inc. engages in the design, development, manufacture, and sale of health and wellness products for food and biomaterials markets. It operates through the following segments: Lifecore, Curation Foods, and Others. The Lifecore segment sells products utilizing hyaluronan, a naturally occurring polysaccharide that is widely distributed in the extracellular matrix of connective tissues in both animals and humans. The Curation Foods segment includes activities to market and pack specialty packaged whole and fresh-cut fruit and vegetables. The Other segment consists of corporate general and administrative expenses, non-Curation Foods and non-Lifecore interest income, and income tax expenses. The company was founded by Ray Stewart on October 31, 1986 and is headquartered in Santa Maria, CA.
Read More

Today's Range

Now: $3.79
Low: $3.36
High: $3.82

50 Day Range

MA: $5.41
Low: $1.67
High: $7.02

52 Week Range

Now: $3.79
Low: $1.52
High: $11.95

Volume

500,726 shs

Average Volume

839,158 shs

Market Capitalization

$114.91 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.11

Frequently Asked Questions

What sell-side analysts currently cover shares of Lifecore Biomedical?

The following equities research analysts have issued stock ratings on Lifecore Biomedical in the last year: Barrington Research, and Stephens.
View the latest analyst ratings for LFCR.

What is the current price target for Lifecore Biomedical?

2 Wall Street analysts have set twelve-month price targets for Lifecore Biomedical in the last year. Their average twelve-month price target is $9.50, suggesting a possible upside of 150.7%. Stephens has the highest price target set, predicting LFCR will reach $11.00 in the next twelve months. Barrington Research has the lowest price target set, forecasting a price of $8.00 for Lifecore Biomedical in the next year.
View the latest price targets for LFCR.

What is the current consensus analyst rating for Lifecore Biomedical?

Lifecore Biomedical currently has 1 hold rating and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe LFCR will outperform the market and that investors should add to their positions of Lifecore Biomedical.
View the latest ratings for LFCR.

What other companies compete with Lifecore Biomedical?

Other companies that are similar to Lifecore Biomedical include InterCure, Affimed, Pieris Pharmaceuticals, Galera Therapeutics and Societal CDMO. Learn More about companies similar to Lifecore Biomedical.

How do I contact Lifecore Biomedical's investor relations team?

Lifecore Biomedical's physical mailing address is 2811 AIRPARK DRIVE, SANTA MARIA CA, 93455. The company's listed phone number is (800) 454-1355 and its investor relations email address is [email protected] The official website for Lifecore Biomedical is www.lifecore.com. Learn More about contacing Lifecore Biomedical investor relations.